|
|
|
Agenda: Conference: Day 1
Monday, June 9, 2003
|
9:00 a.m. |
Welcome and Introduction
Bert Weinstein
Vice President and Assistant General Counsel
Merck & Co.
Whitehouse Station, NJ
|
9:15 a.m. |
Keynote: OIG Overview of the Pharmaceutical Industry Guidance
Lewis Morris, Esq.
Chief Counsel to the Inspector General
Office of Inspector General
Department of Health and Human Services
Washington, DC
|
10:15 a.m. |
Keynote: DOJ Views on Compliance Issues and the Pharmaceutical Industry
Susan Winkler, Esq.
Assistant US Attorney and Deputy Health Care Fraud Chief
Boston, MA
|
11:00 a.m. |
Break
|
11:15 a.m. |
Responding to the Guidance: Compliance Officers Roundtable - Initial Thoughts on the Guidance, Its Implications for the Pharmaceutical Industry, and Insight into How to Operationalize the Guidance
William T. Fitzgerald
Director, Compliance
Alcon Laboratories, Inc.
Fort Worth, TX
Janice Forsyth
Vice President & Chief Compliance Officer
Express Scripts, Inc.
St. Louis, MO
Ann E. Lewis
Senior Corporate Counsel, Pfizer Inc,
New York, NY
Lori Queisser, CPA
Vice President and Chief Compliance Officer
Eli Lilly and Company
Indianapolis, IN
Arjun Rajaratnam, Esq.
Compliance Officer
Global Pharmaceuticals
GlaxoSmithKline
Research Triangle Park, NC
Jeff Stewart
Vice President, Compliance
Ortho Biotech, a Johnson & Johnson Company
Raritan, NJ
Janice Toran
Vice President, Compliance
Fujisawa Healthcare, Inc.
Deerfield, IL
Robert G. Homchick, Esq.
Partner, Davis Wright Tremaine
Seattle, WA
(Moderator)
Presentation Material (Acrobat)
Presentation Material (Powerpoint)
|
12:30 p.m. |
Lunch and Presentations
|
1:00 p.m. |
Industry Responsibilities in the New Age of Corporate Compliance
Jeffrey B. Kindler, Esq.
Senior Vice President and General Counsel
Pfizer Inc.
New York, NY
|
1:30 p.m. |
U.S. Sentencing Commission Views on Corporate Compliance Programs
Charles Tetzlaff, Esq.
General Counsel
U.S. Sentencing Commission
Washington DC
|
2:00 p.m. |
Transition Break
|
2:15 p.m. |
Dissecting the Guidance: An In-Depth Review of the Risk Areas
Patrick Davish
Executive Director, Public Affairs & Policy
Merck & Co, Inc.
North Wales, PA
Stuart Fullerton
Senior Litigation Counsel
AstraZeneca Pharmaceuticals, LLP
Wilmington, DE
Karen R. Lines, Esq.
Associate General Counsel
Genentech, Inc.
South San Francisco, CA
Beth Levine, Esq.
General Counsel, U.S. Pharmaceuticals
Pfizer Inc.
New York, NY
Mary E. Riordan, Esq.
Senior Counsel
Office of Counsel to the Inspector General
Office of Inspector General
Department of Health and Human Services
Washington, DC
John Bentivoglio, Esq.
Partner, Arnold and Porter
Former Special Counsel for Healthcare Fraud
Chief Privacy Officer
United States Department of Justice
Washington, DC
(Moderator)
Presentation Material (Acrobat)
Presentation Material (Powerpoint)
|
3:30 p.m. |
CIAs, IROs and Other Enforcement Issues
Jeffrey M. Greenman, Esq.
Compliance Officer
Bayer Pharmaceuticals Corporation
West Haven, CT
Paul Kalb, MD, JD
Partner, Sidley Austin Brown & Wood
Washington, DC
Douglas M. Lankler, Esq.
Senior Corporate Counsel
Deputy Corporate Compliance Officer
Pfizer Inc.
New York, NY
Presentation Material (Acrobat)
Presentation Material (Powerpoint)
Mary E. Riordan, Esq.
Senior Counsel
Office of Counsel to the Inspector General
Office of Inspector General
Department of Health and Human Services
Washington, DC
Brenton Saunders, JD, MBA
Partner, PricewaterhouseCoopers
Past President, Health Care Compliance Association
Founder and Chair-elect, International Association of Privacy Officers
Washington, DC
(Moderator)
|
4:30 p.m. |
The Role of Internal Audit in Corporate Compliance
Isaac DeLuca
Manager, Internal Audit
Pfizer, Inc.
New York, NY
Hugh M. Donnelly
Vice President, Audit
Pfizer Inc.
New York, NY
Presentation Material (Acrobat)
Presentation Material (Powerpoint)
Bradford W. Kling
Vice President, Corporate Audit
Alcon Laboratories, Inc.
Fort Worth, TX
Chuck Mooney
Director, Internal Audit
Pfizer, Inc.
New York, NY
|
5:15 p.m. |
Adjournment
|
top of page
|
